NewAmsterdam Pharma BV has secured a licensing deal for its lead drug, a cholesterol lowering agent for patients who aren’t well controlled on statins. The partner is the Menarini Group of Italy which already has a cardiology portfolio of 18 products and is prepared to pay up to €1 billion for rights to the new product candidate.
Oncogeni Ltd, a company founded in 2019 by the British scientist and Nobel Laureate Martin Evans is to be acquired by Roquefort Therapeutics Plc in order to progress its preclinical assets for cancer. The all-share transaction, announced on 22 June, has been valued at around £4 million. Concurrently, the enlarged company will have two new investors: Daiichi Sankyo Co Ltd and the venture capital investor CH Health.
F-star Therapeutics Inc is to be acquired by a subsidiary of a large Chinese pharma group giving it a new setting in which to develop its bispecific antibodies for cancer. The acquirer is invoX Pharma, a subsidiary of Sino Biopharmaceutical Ltd which has a portfolio of small molecule drugs and biologics to treat cancer and other diseases.
Ipsen SA is to expand its oncology portfolio with the acquisition of Epizyme Inc, a US developer of epigenetic medicines. Epizyme’s lead product, Tazverik (tazemetostat) has been approved for two cancer indications in the US – diseases that are not covered by Ipsen’s current portfolio.
NOXXON Pharma NV has updated its drug development strategy in light of further positive data for its aptamer drug NOX-A12 in patients with glioblastoma. The company’s resources will now be fully deployed to advance NOX-A12 towards registration. Other research projects will be put on hold, the company announced on 23 June 2022.
Spain-based VIVEbiotech SL has received regulatory approval for an upgrade of its lentiviral vector manufacturing capacity that will significantly expand its ability to produce vectors for both in vivo and ex vivo gene therapies. The company currently has 40 programmes ongoing with four dedicated to in vivo administration.
Bpifrance, the French national investment bank, has issued a grant valued at €10 million to Osivax SAS, a biotech company based in Lyon, to advance development of a broad-spectrum influenza vaccine candidate. The financing is part of a larger initiative by the French government to promote medical innovation and prepare for future pandemics and infectious diseases. Osivax will use the funds to prepare its vaccine, OVX836, for a Phase 2b field efficacy trial against a broad range of circulating influenza strains.
Galapagos NV is to acquire two companies with a presence in cell therapy as it takes steps to broaden its business under new leadership. The Dutch company has reached separate agreements to purchase CellPoint BV, a manufacturing company in the Netherlands, and AboundBio Inc, a US drug discovery company with an antibody library and antibody engineering capabilities.
Faron Pharmaceuticals Ltd of Finland has reported top-line, 12 month survival data for its antibody drug bexmarilimab showing that a significant number of patients who benefited from the treatment were still alive at 12 months. The Phase 1/2 MATINS study is investigating the safety and efficacy of bexmarilimab monotherapy in 10 different metastatic or inoperable solid tumour cohorts.
A Phase 2 study of an experimental Alzheimer’s disease treatment designed to slow or prevent cognitive decline in people carrying a specific genetic mutation failed to meet its primary endpoints, the Roche Group announced on 16 June. The placebo-controlled trial was evaluating the monoclonal antibody crenezumab as a potential treatment for early-onset Alzheimer’s in people carrying the Presenilin 1 E280A mutation.